Company profile
Vifor Pharma
Iron deficiency / nephrology therapeutics (part of CSL group since 2022)
Privately held: no public share price · Switzerland
Assets
(4 total)
4Total Assets
3Approved
1Phase 3 / Filed
0Phase 1–2 / Early
2Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
Difelikefalin(Korsuva) | Approved | Kappa-opioid receptor (agonist, peripherally restricted)Peptide | Chronic Kidney Disease |
Ferric carboxymaltose(Injectafer / Ferinject) | Approved | Iron repletionOther | Heart FailureChronic Kidney Disease |
Sucroferric oxyhydroxide(Velphoro) | Approved | Dietary phosphateSmall molecule | Chronic Kidney Disease |
Patiromer(Veltassa) | Phase 3 | Gastrointestinal potassium binderSmall molecule | Heart FailureChronic Kidney Disease |
Upcoming events
Research
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Research
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.